Avista Pharma Solutions Doubles API Manufacturing Capacity at Colorado Facility
Facility and Equipment Upgrades Support Processing of Potent Compounds
LONGMONT, Colo., November 13, 2017 – Avista Pharma Solutions, Inc. (“Avista Pharma”) has completed facility upgrades that effectively double the company’s API manufacturing capacity at its Longmont, Colorado site. During this expansion, the site’s three existing GMP drug substance manufacturing suites were upgraded, and a fourth GMP suite was added. The facility’s non-GMP capacity was also doubled with the addition of two large-scale development suites.
Among the new equipment installations were four walk-in hoods, three 50-gallon glass-lined reactors, three Hastelloy agitated filter dryers, and various small-scale reactors and mixing vessels. The new, state-of-the-art equipment will provide additional scale and enable processing of complex and potent categories of chemical compounds.
Safety and containment controls were also upgraded during the expansion, giving Avista Pharma the ability to manufacture materials rated up to occupational exposure bands of 3A and 3B by SafeBridge®.
“Our investments in suite upgrades and capacity expansion in Longmont have transformed the site into a world-class API manufacturing facility,” said Ken Domagalski, General Manager of the Avista Pharma Longmont facility. “Our team of experienced scientists prides itself in finding the most efficient path to success for our clients, further demonstrating our facility as a CMC center of excellence.”
The API facility expansion is one of several major investments at the Longmont site during 2017. Avista Pharma is also in the process of expanding its drug product manufacturing capacity and analytical capacity, as well as adding walk-in stability storage chambers into the additional 20,000-square-foot expansion announced last year.
NEW MEDIA CONTENT:
Avista Pharma on Facebook
Avista Pharma on Twitter
Avista Pharma on LinkedIn
ABOUT AVISTA PHARMA SOLUTIONS, INC.:
Avista Pharma Solutions is a contract development, manufacturing, and testing organization that understands what it takes to rapidly advance products through every stage of development. With over 200,000 square feet of laboratory and manufacturing space in the U.S., Avista Pharma offers a broad suite of scientifically differentiated services ranging from early stage discovery, API and Drug Product development and cGMP manufacturing to stand-alone analytical and microbiology testing support. Led by our broad experience and collaborative approach, we are committed to finding the shortest, most efficient path to success for our clients – success that goes beyond science. For more information on how Avista Pharma can help your team succeed, please Contact Us.
ABOUT AMPERSAND CAPITAL PARTNERS:
Ampersand is a middle-market private equity firm with a focus on growth equity investments in the healthcare sector. Over the past two decades, Ampersand has managed more than $1 billion in private equity partnerships. Ampersand leverages its unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Additional information about Ampersand is available at www.ampersandcapital.com.